In a groundbreaking move for the pharmaceutical industry, Varda Space Industries has entered into a partnership with United Therapeutics, aiming to explore the crystallization of drugs in microgravity environments. This innovative venture seeks to determine if the unique conditions of space can lead to the development of pharmaceuticals with enhanced properties, potentially revolutionizing how drugs are manufactured. With the reduction in launch costs and advancements in reusable rocket technology, the idea of producing drugs in orbit is becoming increasingly viable, marking a significant milestone in the evolution of drug development.
Meanwhile, NASA is making strides towards interplanetary exploration with an ambitious project to create the first nuclear reactor-powered spacecraft intended for missions to Mars. Set to launch by 2028, this initiative could redefine the future of space travel and establish the United States as a leader in advanced space technology, especially in light of international competition. Experts have begun to analyze the potential mechanisms and technologies behind such a nuclear-powered vessel, indicating that this endeavor could herald a new era for human exploration beyond Earth. As these initiatives unfold, they underscore the transformative potential of space as a frontier for both pharmaceutical advancements and cutting-edge aerospace engineering.
Source: The Download: making drugs in orbit and NASA’s nuclear-powered spacecraft via MIT Technology Review